Pipeline

R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Mmemme COVID-19  

COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe.

COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA)

VIREX (nchọpụta nchọpụta) N'ụlọ nyocha

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (ọgwụgwọ) Neutralizing Antibody (IV) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ

20%*

FUJOVEE (Abivertinib) COVID-19 siri ike na ndị ọrịa ICU

82%*

Ọnwụnwa dị mkpa na-echere mkpochapụ FDA

OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU

82%*

Ọnwụnwa dị mkpa na Brazil

Mpro Ihe mgbochi (ọgwụ ọnụ) Ọrịa mgbochi

40%*

Omicron mRNA ogwu Vaccine

20%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
immunotherapy  

FUJOVEE (Abivertinib) NSCLC

82%*

FUJOVEE (Abivertinib) B cell Lymphomas

60.2%*

FUJOVEE (Abivertinib) Prostate

20%*

FUJOVEE (Abivertinib) Lupus

20%*

FUJOVEE (Abivertinib) MS

20%*

FUJOVEE (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* Na mmekorita ya na Lee's Pharm na China

PD-L1 (STI-3031)** Ọrịa Cervical

82%*

** Na US yana mmekorita ya na ImmuneOncia na Korea

CD47 Tumor siri ike

40%*

CD38 DAR-T multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal

40%*

Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor

40%*

Ọnụ ego nke BCMA ADC Tumor Liquid

20%*

Bevacizumab-ADNAB™ Ọrịa kansa Endometrial

40%*

Na mmekorita ya na Mayo Clinic

Bevacizumab-ADNAB™ Ọrịa Ovarian

40%*

Na mmekorita ya na Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Na mmekorita ya na Mayo Clinic

Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma

40%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Pain  

ZTlido® 1.8%
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Ọgwụgwọ gout (Oral)

99.8%*

SEMEXA (SP-102) Lumbar Radicular/Sciatica mgbu

82%*

SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu

60.2%*

SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia

20%*

RTX (resiferatoxin)
Epidural injection
Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu

60.3%*

Nhọpụta nwa mgbei

RTX (resiferatoxin)
Ụzọ intra-articular
OA Mgbu OA Na-agafeghị agafe ruo Dị Ike

60.2%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Nnyefe ọgwụ Lymphatic  

Sofusa® mgbochi TNF Autoimmune (RA)

40%*

Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® mgbochi CTLA-4 Melanoma

40%*

Na mmekorita ya na Mayo Clinic
Mmemme COVID-19
Mmemme igodo (Ngosipụta) adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA
COVIMARK™ (nchọpụta nchọpụta) FDA EUA
VIREX (nchọpụta nchọpụta) PH III
COVISHIELD™ (ọgwụgwọ) PH I
FUJOVEE (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Ọgwụ mgbochi (ọgwụ nke ọnụ) Ph II
Omicron mRNA ogwu Mgbochi
immunotherapy
Mmemme igodo (Ngosipụta) adọ
FUJOVEE (Abivertinib) Ph III
FUJOVEE (Abivertinib) Ph II
FUJOVEE (Abivertinib) Mgbochi
FUJOVEE (Abivertinib) Mgbochi
FUJOVEE (Abivertinib) Mgbochi
FUJOVEE (Abivertinib) Mgbochi
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 Tumor siri ike Ph I
CD38 DAR-T (Otu Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I
Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I
Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi
Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I
Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I
Pain
Mmemme igodo (Ngosipụta) adọ
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA
Gloperba® 1.8% Ọgwụgwọ gout (Oral) Nkwado FDA
SEMEXA (SP-102) Ph III
SP-103 (Sistemụ Topical Lidocaine 5.4%) Ph II
SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi
RTX (resiferatoxin) Epidural injection Ph II
RTX (resiferatoxin) Ụzọ intra-articular Ph II
Nnyefe Lymphatic
Mmemme igodo (Ngosipụta) Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I
Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I
Sofusa® mgbochi CTLA-4 (Melanoma) Ph I